Conduit Pharmaceuticals Company Insiders
| CDT Stock | 1.40 0.04 2.78% |
Conduit Pharmaceuticals employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Conduit Pharmaceuticals' management performance can provide insight into the firm performance.
Conduit Pharmaceuticals Management Team Effectiveness
The company has Return on Asset of (2.0695) % which means that on every $100 spent on assets, it lost $2.0695. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Conduit Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Conduit Pharmaceuticals Workforce Comparison
Conduit Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 785. Conduit Pharmaceuticals maintains roughly 6.0 in number of employees contributing less than 1% to equities under Health Care industry.
Conduit Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Conduit Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Conduit Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Conduit Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Regan over three weeks ago Acquisition by Andrew Regan of 224800 shares of Conduit Pharmaceuticals at 1.79 subject to Rule 16b-3 | ||
Kuznik Ferdinand over a month ago Disposition of 200000 shares by Kuznik Ferdinand of Conduit Pharmaceuticals at 14.25 subject to Rule 16b-3 | ||
James Bligh over three months ago Acquisition by James Bligh of 480000 shares of Conduit Pharmaceuticals subject to Rule 16b-3 | ||
Fromm Charles over six months ago Acquisition by Fromm Charles of 15700 shares of Conduit Pharmaceuticals at 10.0 subject to Rule 16b-3 | ||
Fry Simon Jeremy over a year ago Insider Trading | ||
Charles Faith L. over a year ago Acquisition by Charles Faith L. of 75000 shares of Conduit Pharmaceuticals subject to Rule 16b-3 | ||
Nirland Ltd over a year ago Disposition of 1368991 shares by Nirland Ltd of Conduit Pharmaceuticals at 0.1026 subject to Rule 16b-3 | ||
Nirland Ltd over a year ago Disposition of 1500000 shares by Nirland Ltd of Conduit Pharmaceuticals at 0.1043 subject to Rule 16b-3 |
Conduit Pharmaceuticals Notable Stakeholders
A Conduit Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Conduit Pharmaceuticals often face trade-offs trying to please all of them. Conduit Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Conduit Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andrew Regan | Former Founder | Profile | |
| James Bligh | Interim Director | Profile | |
| David Tapolczay | Head Licensing | Profile | |
| Adam Sragovicz | Chief Officer | Profile | |
| Joanne Holland | Chief Officer | Profile | |
| Bill Begien | Senior Relations | Profile |
About Conduit Pharmaceuticals Management Performance
The success or failure of an entity such as Conduit Pharmaceuticals often depends on how effective the management is. Conduit Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Conduit management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Conduit management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Conduit Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Conduit Pharmaceuticals. Check Conduit Pharmaceuticals' Beneish M Score to see the likelihood of Conduit Pharmaceuticals' management manipulating its earnings.
Conduit Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Conduit Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Conduit Pharmaceuticals within its industry.Conduit Pharmaceuticals Manpower Efficiency
Return on Conduit Pharmaceuticals Manpower
| Revenue Per Employee | 153.7M | |
| Revenue Per Executive | 153.7M | |
| Net Loss Per Employee | 3M | |
| Net Loss Per Executive | 3M |
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.